Regeneron Showcases Respiratory Treatments at ERS 2024 Congress

TARRYTOWN, N.Y., Aug. 26, 2024 (GLOBE NEWSWIRE) -- New York-headquartered biotechnology company, Regeneron Pharmaceuticals, Inc. NASDAQ:REGN announced an impressive showcase of research findings with a total of 20 abstracts submitted focusing on their innovative treatments Dupixent® (dupilumab) and the investigational drug itepekimab at the European Respiratory Society (ERS) Congress 2024, which is scheduled to be held from September 7 onwards.

Dupixent® (dupilumab) Highlights at ERS

Dupixent®, also known by its generic name dupilumab, has been a prominent focus in Regeneron's pipeline, demonstrating potential for patients dealing with various respiratory conditions. The medication, co-developed with global healthcare leader Sanofi, seeks to provide relief from symptoms and reduce exacerbations in conditions such as asthma and nasal polyps. The forthcoming ERS Congress will unveil detailed research and clinical trial results for Dupixent®, showcasing its efficacy and safety profile in respiratory disease management.

Emergence of Itepekimab

Trailblazing in the field of respiratory disease is the investigational therapy itepekimab, aimed at targeting pulmonary conditions at their core immunological processes. Studies reveal that itepekimab could revolutionize treatment modalities for diseases like chronic obstructive pulmonary disease (COPD) and other serious respiratory ailments. Research focusing on this novel therapy's effectiveness and possible benefits will take center stage among the 20 abstracts that Regeneron is set to present at the ERS Congress.

Investor Outlook on Regeneron's Innovation

Investors and observers of the biopharmaceutical sector are closely monitoring these developments as they may signal further growth for Regeneron. The company's ongoing contribution to pioneering respiratory treatments resonates with its commitment to science-led innovation, potentially bolstering its market position and impacting its stock valuation NASDAQ:REGN. This representation at a leading respiratory conference may pave the way for increased investor confidence in Regeneron's direction and future prospects within the industry.

Regeneron, Dupixent, Itepekimab